Telix Expands Prostate Cancer Activity with GenesisCare Collaboration
Melbourne (Australia) – 19 August 2021. Telix releases details of two ancillary studies under the ProstACT program, including a Phase II study in collaboration with GenesisCare.
Telix has today released details of two ancillary studies under the ProstACT program that significantly extend the evaluation of Telix’s TLX591 antibody-directed 177Lu (lutetium) therapeutic platform into areas of unmet medical need across the full prostate cancer treatment journey.
The two additional studies will run alongside the Phase III ProstACT GLOBAL study. This expanded ProstACT study program scope will enable Telix to evaluate the efficacy and safety of PSMA-targeted lutetium therapy in early-stage, localised disease all the way through to advanced metastatic disease (known as metastatic castrate-resistant prostate cancer, or mCRPC).
The two additional studies are:
- ProstACT SELECT, a Phase I radiogenomics study with the goal of comparing 68Ga-PSMA (gallium) and 177Lu-PSMA (lutetium), specifically exploring the biodistribution differences between small molecule and antibody-based targeting. The study is designed to inform optimal patient selection for Telix’s antibody-based 177Lu therapy, with the goal of enabling indication expansion for Telix’s PSMA therapeutic portfolio. ProstACT SELECT is a multi-centre study and will enrol up to 50 patients.
- ProstACT TARGET, a Phase II study to evaluate TLX591 in combination with external beam radiation therapy (EBRT) in patients with oligometastatic prostate-specific membrane antigen (PSMA) expressing disease, providing data in early prostate cancer relapse. The study, which targets enrolment of 50 patients across multiple Australian sites, is a collaboration with Telix’s strategic partner, GenesisCare, and will be conducted within its network. GenesisCare will co-fund the study alongside Telix.
This expanded study program will inform the Company’s long-term clinical and commercialisation strategies for the TLX591 therapeutic candidate and generate multiple opportunities for near-term data readouts throughout the program duration.
Telix CEO Dr Christian Behrenbruch commented, “Telix’s ultimate objective is to evaluate the use of our PSMA-targeting radionuclide therapies in prostate cancer from first diagnosis to advanced metastatic disease. The biology of prostate cancer and clinical utility of radionuclide therapy will have distinct application in each of these settings. We believe there is a clear rationale for integrating molecularly-targeted radiation (MTR) with standard of care at each stage in the patient journey and these earlier studies have potential to rapidly expand the scope of future clinical indications.”
GenesisCare Founder and CEO Dan Collins added, “We continue to be excited about our collaborative work with Telix to unlock the potential of PSMA as a therapeutic target for the treatment of prostate cancer. Through GenesisCare’s extensive network of cancer care centers, our partnership with Telix on the Phase II ProstACT TARGET trial will enable us to accelerate our scientific understanding of early biochemical recurrence (BCR) and oligometastatic prostate cancer with the potential to improve life outcomes for patients as we shorten the timeline between the development and use of the newest treatment options.”
To read the full ASX disclosure please click here.
To return to the Telix homepage please click here.